CLEC9A and cancer: While DNGR-1 can be targeted with antigens bound to antibodies, directed peptides, or F-actin/myosin-coated beads to vaccinate against tumors (10, 23, 24), the in vivo role of DNGR-1 in cancer immunity has not been addressed yet.